Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
Belite Bio (NASDAQ: BLTE) has appointed Dr. Hendrik P. N. Scholl as its new Chief Medical Officer. Dr. Scholl is a globally recognized expert in ophthalmology, specializing in Stargardt disease and age-related macular degeneration (AMD). He brings decades of experience to Belite Bio's lead drug candidate, Tinlarebant, which targets these conditions.
Dr. Scholl's impressive career includes founding the Institute of Molecular and Clinical Ophthalmology Basel, serving as Professor of Ophthalmology at the University of Basel, and holding leadership positions at Johns Hopkins University. He is the coordinating principal investigator of the largest natural history study of Stargardt disease and has authored over 280 peer-reviewed articles.
Belite Bio (NASDAQ: BLTE) ha nominato Dr. Hendrik P. N. Scholl come nuovo Direttore Medico. Il Dr. Scholl è un esperto riconosciuto a livello globale in oftalmologia, specializzato nella malattia di Stargardt e nella degenerazione maculare legata all'età (AMD). Porta con sé decenni di esperienza nel candidato principale di farmaco di Belite Bio, Tinlarebant, che mira a trattare queste condizioni.
La carriera impressionante del Dr. Scholl include la fondazione dell'Istituto di Oftalmologia Molecolare e Clinica di Basilea, l'incarico di Professore di Oftalmologia all'Università di Basilea e ruoli di leadership presso la Johns Hopkins University. È il principale ricercatore coordinatore del più grande studio sulla storia naturale della malattia di Stargardt e ha pubblicato oltre 280 articoli sottoposti a revisione paritaria.
Belite Bio (NASDAQ: BLTE) ha nombrado al Dr. Hendrik P. N. Scholl como su nuevo Director Médico. El Dr. Scholl es un experto reconocido a nivel mundial en oftalmología, especializado en la enfermedad de Stargardt y la degeneración macular asociada a la edad (AMD). Aporta décadas de experiencia al candidato principal de fármacos de Belite Bio, Tinlarebant, que se enfoca en estas condiciones.
La impresionante carrera del Dr. Scholl incluye la fundación del Instituto de Oftalmología Molecular y Clínica de Basilea, el cargo de Profesor de Oftalmología en la Universidad de Basilea y posiciones de liderazgo en la Universidad Johns Hopkins. Es el investigador principal coordinador del estudio de historia natural más grande de la enfermedad de Stargardt y ha escrito más de 280 artículos revisados por pares.
Belite Bio(NASDAQ: BLTE)는 Dr. Hendrik P. N. Scholl을 새로운 Chief Medical Officer로 임명했습니다. Scholl 박사는 안과학 분야에서 세계적으로 인정받는 전문가로, 스타가르트병 및 노화 관련 황반변성(AMD)을 전문으로 하고 있습니다. 그는 Belite Bio의 주요 약물 후보인 Tinlarebant에 수십 년간의 경험을 가져다 주며, 이 약물은 이러한 질환을 타겟으로 합니다.
Scholl 박사의 인상적인 경력에는 바젤의 분자 및 임상 안과학 연구소 설립, 바젤 대학교 안과학 교수직 수행, 그리고 존스 홉킨스 대학교에서의 리더십 직책이 포함됩니다. 그는 스타가르트병의 가장 큰 자연사 연구의 주요 조정 연구원이며, 280편 이상의 동료 검토 논문을 저술하였습니다.
Belite Bio (NASDAQ: BLTE) a nommé le Dr Hendrik P. N. Scholl comme nouveau Directeur Médical. Le Dr Scholl est un expert reconnu mondialement en ophtalmologie, spécialisé dans la maladie de Stargardt et la dégénérescence maculaire liée à l'âge (DMLA). Il apporte des décennies d'expérience à la candidate principale de médicament de Belite Bio, Tinlarebant, qui cible ces affections.
La carrière impressionnante du Dr Scholl comprend la fondation de l'Institut d'Ophthalmologie Moléculaire et Clinique de Bâle, son poste de Professeur d'Ophthalmologie à l'Université de Bâle et des postes de direction à l'Université Johns Hopkins. Il est le chercheur principal coordonnateur de la plus grande étude de l'histoire naturelle de la maladie de Stargardt et a publié plus de 280 articles examinés par des pairs.
Belite Bio (NASDAQ: BLTE) hat Dr. Hendrik P. N. Scholl zu seinem neuen
Die beeindruckende Karriere von Dr. Scholl umfasst die Gründung des Instituts für Molekulare und Klinische Ophthalmologie in Basel, die Tätigkeit als Professor für Ophthalmologie an der Universität Basel und leitende Positionen an der Johns Hopkins University. Er ist der koordinierende Hauptforscher der größten Studie zur natürlichen Geschichte der Stargardt-Krankheit und hat über 280 wissenschaftliche Artikel veröffentlicht.
- Appointment of a globally recognized expert in ophthalmology as Chief Medical Officer
- New CMO brings decades of experience in Stargardt disease and AMD, aligning with Belite Bio's focus
- Dr. Scholl's involvement validates the potential of Tinlarebant for treating macular diseases
- Addition of expertise may accelerate clinical program development
- None.
- Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease
SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargardt disease and age-related macular degeneration (AMD), bringing decades of expertise in treating retinal diseases, including the two key indications targeted by Belite Bio's lead drug candidate, Tinlarebant.
“Dr. Scholl has pioneered some of the most significant ophthalmology advancements of our time, and we are incredibly honored and excited to welcome him as our Chief Medical Officer,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “Dr. Scholl has served as Chair of the Data and Safety Monitoring Board for both our Phase 2 and Phase 3 Stargardt disease trials, and his decision to join Belite further validates our belief in Tinlarebant’s immense potential to improve the lives of patients living with debilitating macular diseases. His leadership, expertise, and commitment to addressing this area of high unmet need has and will continue to be invaluable as we advance our clinical programs.”
“I am excited to join Belite Bio at this pivotal time in the Company’s development,” said Dr. Scholl. “I have dedicated my career to improving the lives of people suffering from serious retinal and macular diseases, and I am deeply impressed by Belite Bio’s pioneering approach to developing transformative therapies for Stargardt disease and dry AMD, which have historically lacked effective treatment options. I look forward to working with the team to advance these programs and bring hope to patients around the world.”
Dr. Scholl served as the founding and scientific co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Professor of Ophthalmology at the University of Basel, where he also led the Department of Ophthalmology as its Chairman. He currently serves as President of the European Vision Institute as well as Chairman of the largest clinical research network in ophthalmology in Europe, EVICR.net, and its Expert Committee on Retinal Dystrophies. He is also the Founder and President of the Swiss Association for Research in Vision and Ophthalmology (ARVO-SWISS).
Dr. Scholl’s distinguished career in academia includes leadership positions at several key academic institutions. Recently, he served as Professor of Ophthalmology and Endowed Chair at the Wilmer Eye Institute of Johns Hopkins University Medical School. At the Johns Hopkins Hospital, he was the Head of the Retinal Degeneration Clinic and the Director of the Visual Neurophysiology Service. For the Wilmer Eye Institute, he also served as the Co-director of the Johns Hopkins Center for Stem Cells and Ophthalmic Regenerative Medicine.
Dr. Scholl is the coordinating principal investigator of the largest natural history study of Stargardt disease (ProgStar Study), which enrolled 365 subjects. Throughout his career, he has participated in over 10 clinical studies both in Stargardt disease and AMD, authored over 280 articles and reviews in peer-reviewed journals, and received numerous prestigious awards, including the European Vision Award, the President’s Award of the American Society of Retinal Specialists, the W. Richard Green Award and the Paul Henkind Memorial Award of the Macula Society, the Swiss Alfred-Vogt Award, and the Kupfer award of ARVO. He holds an honorary doctorate from Semmelweis University in Budapest, Hungary, and is Adjunct Professor at the Medical University of Vienna, Austria.
Over the course of his 25 years of experience, Dr. Scholl has led and participated in numerous boards and advisory committees. He currently serves on the Scientific Advisory Board of Pro Retina Deutschland, Foundation Fighting Blindness, Erasmus University Medical Center, AIBILI, and the Institut de la Vision (Paris); on the Investment Advisory Board of Droia NV; and the Data Safety Monitoring Board of Roche Holding AG and ViGeneron GmbH.
Dr. Scholl graduated from the University of Tübingen, Germany with a Doctor of Medicine (Dr. med.) and Master of Arts. He completed his specialist training at the University Eye Hospital in Tübingen before being awarded a fellowship from the German Research Foundation (DFG) at Moorfields Eye Hospital and Institute of Ophthalmology in London, and a DFG Heisenberg Professorship for Macular Diseases at the Eye Clinic of the University of Bonn, Germany.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs such as Stargardt Disease and Geographic Atrophy in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent Stargardt subjects and a Phase 3 study (PHOENIX) in subjects with Geographic Atrophy. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu : ir@belitebio.com
Julie Fallon : belite@argotpartners.com
FAQ
Who is Belite Bio's new Chief Medical Officer?
What is Dr. Scholl's expertise in relation to Belite Bio's (BLTE) focus?
What significant study has Dr. Scholl led that's relevant to Belite Bio (BLTE)?
How might Dr. Scholl's appointment impact Belite Bio's (BLTE) clinical programs?
